Moderator: Shuka Zernovizky, CEO, SemIsrael & MDI
SemIsrael & MDI
09:00 - 09:10
CEO and Co-founder
09:10 - 09:30
Re-opening Workspaces Through Covid Screening
The importance of finding a reliable, quick and simple method for screening masses for covid-19 has been highlighted recently, due to an outbreak in the White House. Off-label use of current diagnostic tools cannot replace proper screening systems. Thus, there is a growing need for point-of-care tests, which can facilitate safe spaces and mass health management. Such need is not only applicable to covid - screening tests are few, at most, in all industries.
NanoScent puts its focus on utilizing scent recognition to answer these needs, by developing a cutting edge, affordable and easy-to-use screening device. This testing method combines complex organic chemistry, high-tech mechanics and advanced machine learning algorithms. From industrial leaks compromising the ecology to infections jeopardizing our health - if it has a scent, we can screen it.
Oren Gavriely is the co-founder and CEO at NanoScent, the world’s ecosystem for scent recognition, enabling devices to detect scents. Prior to that, Oren founded BeatMed.com. Oren managed OHK Medical Devices, Inc. establishing HemaClear as the gold standard of care in orthopedic surgery. He also co-founded ETVIEW (Sold to Ambu), a device company developing airway management solutions, and helped found MooNa: Space for Change, a culturally rooted social venture. Oren is a prolific inventor credited with five medical device technologies and vast experience with healthcare professionals. He received a degree in Mechanical Engineering from the Technion-Israel Institute of Technology.
09:30 - 09:50
2020 Digital Health Tipping Point Year – Opportunities and Challenges
Can Digital Health be considered as the frontier sector for investments this year? To what degree has the COVID-19 pandemic accelerated sectoral trends of recent years? Will consumers behaviour and capacity for providers suggest virtual care solutions are here to stay?
Michal is the Co-Founder and Managing Partner of Triventures and brings over 25 years of experience in medtech and digital health in Israel and the U.S. She co-founded Triventures in 2010 to provide what was then missing in the ecosystem- a deep understanding of commercial integration of innovative technologies into the healthcare system. Triventures was one of the first funds in to focus on digital health in Israel and Michal was the first woman to found and manage a venture capital firm in Israel. Since founding Triventures, Michal has grown the fund into a multi-stage investment platform and industry leader.
Prior to launching Triventures, Michal served for many years in the healthcare start-up ecosystem and held multiple executive positions with GI View, Advanced Stent Technologies (acquired by Boston Scientific), ByPass, TriReme Medical (IPO) and others. Michal ran several business departments from operations to regulatory and marketing and helped scale and steer the companies towards successful exits.
In 2017, Michal was recognized as one of the 50 most influential women in Israel by Globes, Israel’s leading financial journal and in 2011 she was recognized as one of the 40 most promising leaders in Israel by The Marker, Israel’s leading business journal.
With a hands-on approach, Michal is involved in all the fund’s major decisions, leads investments and serves as an active board member in the majority of the portfolio companies.
Head of aMoon Alpha & Investment Lead
09:50 - 10:10
What do VCs Look For in MedTech Opportunities?
Venture Capital funds often define themselves by verticals of interest. These could take a variety of forms – therapeutic areas of focus, business models, or industry segments. Healthcare and life-science VCs traditionally positioned themselves as Biopharma, MedTech (Medical Devices) and (more recently) Digital Health-focused. Israel has seen a good amount of MedTech companies created and an impressive number of exits in this space. Surprisingly, the number of local MedTech funds and angel investors has been gradually decreasing. My presentation will offer a glimpse into why this may be happening, and what non-MedTech funds may find appealing in these opportunities even if they are not focused on this segment.
Dr. Yaron Daniely is the Head of aMoon Alpha, and an Investment lead at aMoon Velocity.
Alpha is an internal aMoon unit charged with translating the fund's unique scale and talent capabilities to concrete, “unfair advantages” for our portfolio companies. aMoon Velocity is our early stage fund that pursues disruptive, cutting-edge technologies with the potential to accelerate cure.
Before joining aMoon, Dr. Daniely was President & CEO of Yissum, the Hebrew University's renowned Technology Transfer Company, and the co-chairperson of the Israel Technology Transfer Network – ITTN. Before joining Yissum in 2017, he spent 14 years as a senior executive (including 10 years as CEO) in private and NASDAQ-traded Biopharma and Biotech companies.
Yaron earned his PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral program, Yaron served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Yaron also holds an MBA degree from the Technion-Israel Institute of Technology.
SemIsrael & MDI
10:10 - 10:30
Moderated Q&A Session, with all three keynote speakers:
Oren Gavriely, CEO and Co-founder, NanoScent
Orli Tori, Partner, Triventures
Yaron Daniely, PhD MBA, Head of aMoon Alpha & Investment Lead, aMoon Velocity